Clinical trial / 2015
Oral nicotinamide reduced the rate of new nonmelanoma skin cancers by 23% over 12 months in high-risk patients.
In a phase 3 trial, 386 high-risk participants were randomized to receive 500 mg of nicotinamide twice daily or placebo for 12 months, followed by a 6-month postintervention period. At 12 months, the rate of new nonmelanoma skin cancers was 23% lower in the nicotinamide group compared to placebo (95% CI, 4 to 38; P=0.02). Rates were 20% lower for basal-cell carcinomas (P=0.12) and 30% lower for squamous-cell carcinomas (P=0.05). Actinic keratoses counts were significantly lower in the nicotinamide group at 3, 6, 9, and 12 months, but benefits were not sustained after discontinuation.
- Study type
- Phase 3 double-blind randomized controlled trial
- Who was studied
- 386 participants with at least two nonmelanoma skin cancers in the previous 5 years
- What was measured
- Number of new nonmelanoma skin cancers during the 12-month intervention period
THE PAPER
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. N Engl J Med, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.